PMID- 37760895
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20231003
IS  - 2227-9059 (Print)
IS  - 2227-9059 (Electronic)
IS  - 2227-9059 (Linking)
VI  - 11
IP  - 9
DP  - 2023 Sep 4
TI  - Combining Celiac and Hepatic Vagus Nerve Neuromodulation Reverses Glucose 
      Intolerance and Improves Glycemic Control in Pre- and Overt-Type 2 Diabetes 
      Mellitus.
LID - 10.3390/biomedicines11092452 [doi]
LID - 2452
AB  - Neurological disorders and type 2 diabetes mellitus (T2DM) are deeply 
      intertwined. For example, autonomic neuropathy contributes to the development of 
      T2DM and continued unmanaged T2DM causes further progression of nerve damage. 
      Increasing glycemic control has been shown to prevent the onset and progression 
      of diabetic autonomic neuropathies. Neuromodulation consisting of combined 
      stimulation of celiac vagal fibers innervating the pancreas with concurrent 
      electrical blockade of neuronal hepatic vagal fibers innervating the liver has 
      been shown to increase glycemic control in animal models of T2DM. The present 
      study demonstrated that the neuromodulation reversed glucose intolerance in 
      alloxan-treated swine in both pre- and overt stages of T2DM. This was 
      demonstrated by improved performance on oral glucose tolerance tests (OGTTs), as 
      assessed by area under the curve (AUC). In prediabetic swine (fasting plasma 
      glucose (FPG) range: 101-119 mg/dL) the median AUC decreased from 31.9 AUs (IQR = 
      28.6, 35.5) to 15.9 AUs (IQR = 15.1, 18.3) p = 0.004. In diabetic swine (FPG 
      range: 133-207 mg/dL) the median AUC decreased from 54.2 AUs (IQR = 41.5, 56.6) 
      to 16.0 AUs (IQR = 15.4, 21.5) p = 0.003. This neuromodulation technique may 
      offer a new treatment for T2DM and reverse glycemic dysregulation at multiple 
      states of T2DM involved in diabetic neuropathy including at its development and 
      during progression.
FAU - Waataja, Jonathan J
AU  - Waataja JJ
AD  - ReShape Lifesciences Inc., Irvine, CA 92618, USA.
FAU - Asp, Anders J
AU  - Asp AJ
AD  - Department of Physical Medicine and Rehabilitation, Mayo Clinic, Rochester, MN 
      55605, USA.
FAU - Billington, Charles J
AU  - Billington CJ
AD  - Minnesota Veterans' Administration Medical Center, Minneapolis, MN 55417, USA.
LA  - eng
GR  - R43 DK122846/DK/NIDDK NIH HHS/United States
PT  - Journal Article
DEP - 20230904
PL  - Switzerland
TA  - Biomedicines
JT  - Biomedicines
JID - 101691304
PMC - PMC10525327
OTO - NOTNLM
OT  - bioelectronics
OT  - glycemic dysregulation
OT  - heart rate variability and vagal tone
OT  - neurological disorders
OT  - neuromodulation
OT  - neuropathy
OT  - type 2 diabetes
OT  - vagus nerve
OT  - vagus nerve stimulation
COIS- Jonathan J. Waataja is an employee of ReShape Lifesciences Inc., which is 
      developing the technology involved in the manuscript. Anders Asp and Charles 
      Billington do not have any conflicts of interest.
EDAT- 2023/09/28 06:43
MHDA- 2023/09/28 06:44
PMCR- 2023/09/04
CRDT- 2023/09/28 01:09
PHST- 2023/07/31 00:00 [received]
PHST- 2023/08/16 00:00 [revised]
PHST- 2023/08/18 00:00 [accepted]
PHST- 2023/09/28 06:44 [medline]
PHST- 2023/09/28 06:43 [pubmed]
PHST- 2023/09/28 01:09 [entrez]
PHST- 2023/09/04 00:00 [pmc-release]
AID - biomedicines11092452 [pii]
AID - biomedicines-11-02452 [pii]
AID - 10.3390/biomedicines11092452 [doi]
PST - epublish
SO  - Biomedicines. 2023 Sep 4;11(9):2452. doi: 10.3390/biomedicines11092452.